- Ginkgo Bioworks Holdings Inc (NYSE:DNA) collaborated with Merck & Co Inc (NYSE:MRK) to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts.
- Through this collaboration, Ginkgo will leverage its experience in cell engineering and enzyme design and its capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics, and analytics to deliver optimal strains for the expression of targeted biocatalysts.
- Also read: Cathie Wood Favorite Ginkgo Bioworks Bolsters Biosecurity Platform Via This Acquisition.
- Under the terms of the collaboration, Ginkgo will earn an upfront research and development fee and is eligible for success-based research and development milestone payments.
- In addition, Ginkgo is eligible to earn commercial milestone payments for each of a specified number of biocatalysis targets, which have the potential to total, in the aggregate, up to $144 million.
- Price Action: DNA shares are up 5.19% at $3.04 on the last check Tuesday.
Inari Medical Announces Results From The Fully Enrolled 800-patient US Cohort Of The FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive
